KARUNA THERAPEUTICS INC COM has a consensus price target of $234.75, established from looking at the 75 latest analyst ratings. The last 3 analyst ratings were released from HC Wainwright & Co., HC Wainwright & Co., and Cantor Fitzgerald on March 14, 2024, March 11, 2024, and February 20, 2024. With an average price target of $330 between HC Wainwright & Co., HC Wainwright & Co., and Cantor Fitzgerald, there's an implied 0.05% upside for KARUNA THERAPEUTICS INC COM from these 3 analyst ratings.
1calculated from analyst ratings published within the last 3 years
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
---|---|---|---|---|---|---|---|---|---|---|---|
03/14/2024 | KRTX | Buy Now | Karuna Therapeutics | $329.83 | 0.05% | HC Wainwright & Co. | Raghuram Selvaraju | $330 → $330 | Maintains | Neutral | Get Alert |
03/11/2024 | KRTX | Buy Now | Karuna Therapeutics | $329.83 | 0.05% | HC Wainwright & Co. | Raghuram Selvaraju | → $330 | Reiterates | Neutral → Neutral | Get Alert |
02/20/2024 | KRTX | Buy Now | Karuna Therapeutics | $329.83 | 0.05% | Cantor Fitzgerald | Charles Duncan | → $330 | Reiterates | Neutral → Neutral | Get Alert |
01/26/2024 | KRTX | Buy Now | Karuna Therapeutics | $329.83 | 0.05% | Mizuho | Vamil Divan | $245 → $330 | Downgrade | Buy → Neutral | Get Alert |
01/17/2024 | KRTX | Buy Now | Karuna Therapeutics | $329.83 | 0.05% | Cantor Fitzgerald | Charles Duncan | → $330 | Reiterates | Neutral → Neutral | Get Alert |
12/28/2023 | KRTX | Buy Now | Karuna Therapeutics | $329.83 | 0.05% | JP Morgan | Jessica Fye | $217 → $330 | Downgrade | Overweight → Neutral | Get Alert |
12/26/2023 | KRTX | Buy Now | Karuna Therapeutics | $329.83 | 0.05% | HC Wainwright & Co. | Raghuram Selvaraju | $300 → $330 | Downgrade | Buy → Neutral | Get Alert |
12/22/2023 | KRTX | Buy Now | Karuna Therapeutics | $329.83 | — | JMP Securities | Jason Butler | — | Downgrade | Market Outperform → Market Perform | Get Alert |
12/22/2023 | KRTX | Buy Now | Karuna Therapeutics | $329.83 | 0.05% | Wedbush | Laura Chico | → $330 | Downgrade | Outperform → Neutral | Get Alert |
12/22/2023 | KRTX | Buy Now | Karuna Therapeutics | $329.83 | — | Guggenheim | Yatin Suneja | — | Downgrade | Buy → Neutral | Get Alert |
12/22/2023 | KRTX | Buy Now | Karuna Therapeutics | $329.83 | 0.05% | Morgan Stanley | Jeffrey Hung | $295 → $330 | Downgrade | Overweight → Equal-Weight | Get Alert |
12/12/2023 | KRTX | Buy Now | Karuna Therapeutics | $329.83 | -31.18% | Deutsche Bank | Neena Bitritto-Garg | → $227 | Initiates | → Buy | Get Alert |
11/20/2023 | KRTX | Buy Now | Karuna Therapeutics | $329.83 | -9.04% | HC Wainwright & Co. | Raghuram Selvaraju | → $300 | Reiterates | Buy → Buy | Get Alert |
11/17/2023 | KRTX | Buy Now | Karuna Therapeutics | $329.83 | -3.59% | JMP Securities | Jason Butler | → $318 | Reiterates | Market Outperform → Market Outperform | Get Alert |
11/17/2023 | KRTX | Buy Now | Karuna Therapeutics | $329.83 | -23.29% | Wedbush | Laura Chico | → $253 | Reiterates | Outperform → Outperform | Get Alert |
11/03/2023 | KRTX | Buy Now | Karuna Therapeutics | $329.83 | -31.78% | RBC Capital | Brian Abrahams | $235 → $225 | Maintains | Outperform | Get Alert |
11/03/2023 | KRTX | Buy Now | Karuna Therapeutics | $329.83 | -10.26% | Goldman Sachs | Corinne Jenkins | $332 → $296 | Maintains | Buy | Get Alert |
11/03/2023 | KRTX | Buy Now | Karuna Therapeutics | $329.83 | -23.29% | Wedbush | Laura Chico | $250 → $253 | Maintains | Outperform | Get Alert |
09/28/2023 | KRTX | Buy Now | Karuna Therapeutics | $329.83 | -9.04% | HC Wainwright & Co. | Raghuram Selvaraju | → $300 | Reiterates | Buy → Buy | Get Alert |
The latest price target for KARUNA THERAPEUTICS INC COM (NASDAQ: KRTX) was reported by HC Wainwright & Co. on March 14, 2024. The analyst firm set a price target for $330.00 expecting KRTX to rise to within 12 months (a possible 0.05% upside). 38 analyst firms have reported ratings in the last year.
The latest analyst rating for KARUNA THERAPEUTICS INC COM (NASDAQ: KRTX) was provided by HC Wainwright & Co., and KARUNA THERAPEUTICS INC COM maintained their neutral rating.
There is no last upgrade for KARUNA THERAPEUTICS INC COM.
The last downgrade for KARUNA THERAPEUTICS INC COM happened on January 26, 2024 when Mizuho changed their price target from $245 to $330 for KARUNA THERAPEUTICS INC COM.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of KARUNA THERAPEUTICS INC COM, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for KARUNA THERAPEUTICS INC COM was filed on March 14, 2024 so you should expect the next rating to be made available sometime around March 14, 2025.
While ratings are subjective and will change, the latest KARUNA THERAPEUTICS INC COM (KRTX) rating was a maintained with a price target of $330.00 to $330.00. The current price KARUNA THERAPEUTICS INC COM (KRTX) is trading at is $329.83, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.